全文获取类型
收费全文 | 1186篇 |
免费 | 124篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 24篇 |
妇产科学 | 8篇 |
基础医学 | 132篇 |
口腔科学 | 25篇 |
临床医学 | 130篇 |
内科学 | 189篇 |
皮肤病学 | 30篇 |
神经病学 | 62篇 |
特种医学 | 27篇 |
外科学 | 310篇 |
综合类 | 40篇 |
一般理论 | 3篇 |
预防医学 | 137篇 |
眼科学 | 6篇 |
药学 | 90篇 |
肿瘤学 | 95篇 |
出版年
2021年 | 20篇 |
2020年 | 15篇 |
2019年 | 22篇 |
2018年 | 20篇 |
2017年 | 30篇 |
2016年 | 26篇 |
2015年 | 24篇 |
2014年 | 30篇 |
2013年 | 44篇 |
2012年 | 44篇 |
2011年 | 33篇 |
2010年 | 25篇 |
2009年 | 37篇 |
2008年 | 44篇 |
2007年 | 51篇 |
2006年 | 46篇 |
2005年 | 43篇 |
2004年 | 40篇 |
2003年 | 32篇 |
2002年 | 49篇 |
2001年 | 31篇 |
2000年 | 45篇 |
1999年 | 42篇 |
1998年 | 14篇 |
1997年 | 12篇 |
1996年 | 13篇 |
1995年 | 14篇 |
1993年 | 13篇 |
1992年 | 40篇 |
1991年 | 26篇 |
1990年 | 23篇 |
1989年 | 12篇 |
1988年 | 22篇 |
1987年 | 26篇 |
1986年 | 18篇 |
1985年 | 27篇 |
1984年 | 16篇 |
1983年 | 16篇 |
1982年 | 13篇 |
1979年 | 9篇 |
1978年 | 19篇 |
1976年 | 12篇 |
1975年 | 17篇 |
1974年 | 13篇 |
1973年 | 14篇 |
1972年 | 13篇 |
1969年 | 15篇 |
1968年 | 11篇 |
1967年 | 9篇 |
1966年 | 13篇 |
排序方式: 共有1310条查询结果,搜索用时 15 毫秒
1.
2.
3.
M. S. Beer J. A. Stanton Y. Bevan A. Heald A. J. Reeve L. J. Street V. G. Matassa R. J. Hargreaves D. N. Middlemiss 《British journal of pharmacology》1993,110(3):1196-1200
1. The 5-hydroxytryptamine (5-HT) receptor binding selectivity profile of a novel, potent 5-HT1D receptor agonist, L-694,247 (2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl ]- 1H-indole-3-yl]ethylamine) was assessed and compared with that of the 5-HT1-like receptor agonist, sumatriptan. 2. L-694,247 had an affinity (pIC50) of 10.03 at the 5-HT1D binding site and 9.08 at the 5-HT1B binding site (sumatriptan: pIC50 values 8.22 and 5.94 respectively). L-694,247 retained good selectivity with respect to the 5-HT1A binding site (pIC50 = 8.64), the 5-HT1C binding site (6.42), the 5-HT2 binding site (6.50) and the 5-HT1E binding site (5.66). The pIC50 values for sumatriptan at these radioligand binding sites were 6.14, 5.0, < 5.0 and 5.64 respectively. Both L-694,247 and sumatriptan were essentially inactive at the 5-HT3 recognition site. 3. L-694,247, like sumatriptan, displayed a similar efficacy to 5-HT in inhibiting forskolin-stimulated adenylyl cyclase in guinea-pig substantia nigra although L-694,247 (pEC50 = 9.1) was more potent than sumatriptan (6.2) in this 5-HT1D receptor mediated functional response. L-694,247 (pEC50 = 9.4) was also more potent than sumatriptan (6.5) in a second 5-HT1D receptor mediated functional response, the inhibition of K(+)-evoked [3H]-5-HT release from guinea-pig frontal cortex slices.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
4.
5.
Reeve Bryce B. Hays Ron D. Chang Chih-Hung Perfetto Eleanor M. 《Quality of life research》2007,16(1):1-8
Background Health-related quality of life (HRQL) is an accepted outcome measure in patients with mood and anxiety disorders. Yet, surprisingly
little attention has been paid to the determinants. In this paper we test the hypothesis that it is associated with personality
traits while controlling for mental disorders.
Methods A large sample of outpatients (n=640) with mood and anxiety disorders was studied. The empirically supported five factor model
of normal personality traits was assessed using the NEO-FFI and includes: neuroticism, extraversion, openness to experience,
agreeableness, and conscientiousness. Mental disorders were assessed with the CIDI, and HRQL with the SF-36.
Results Regression analyses revealed that the NEO-FFI scores, with the exception of conscientiousness, were significantly associated
with SF-36 subscales and summary scores, independently from the mental disorders. The percentage of explained variance due
to the personality traits was highest for the subscales Vitality (10.0%), Mental Health (13.3%) and the Mental Health Summary
Score (9.5%). Furthermore, specific personality traits were related to specific SF-36 subscales.
Conclusions A low HRQL of patients with mood or anxiety disorders is not only determined by the disease or the current health but is also
shaped by personality traits that are relatively stable throughout an individual's life time. 相似文献
6.
7.
What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures? 总被引:1,自引:0,他引:1
8.
P. Lips MD C. Cooper D. Agnusdei F. Caulin P. Egger O. Johnell J. A. Kanis U. Liberman H. Minne J. Reeve J. Y. Reginster M. C. de Vernejoul I. Wiklund 《Osteoporosis international》1997,7(1):36-38
The morbidity of osteoporosis is caused by fractures. Vertebral fractures lead to pain and disability and a decrease in quality of life. A Working Party of the European Foundation for Osteoporosis has developed a specific questionnaire for patients with established vertebral osteoporosis. This questionnaire is intended for use in clinical trials. The questionnaire consists of questions and visual analogue scales in the following domains: pain, activities of daily living, jobs around the house, mobility, leisure and social activities, general health perception and mood. The questionnaire has been translated from English into French, German, Italian, Hebrew, Swedish and Dutch. The questionnaire is currently being validated in a multicentre study involving patients with stable osteoporosis and control subjects. Preliminary results indicate that the reproducibility is sufficient and that the questionnaire is able to discriminate between patients with vertebral osteoporosis and control subjects. 相似文献
9.
T S Reeve 《The British journal of surgery》1988,75(9):833-834
10.